Choose a medtech PR agency around the milestone you need to explain, the evidence you can use and the people you need to reach. Percepture’s public relations services are a starting point when that brief needs coordinated communications support.
A recognizable agency name is not enough. Compare how each team handles scientific detail, claim review, editorial relationships and the handoff from public attention to a useful buyer conversation.
What does a MedTech PR agency do?
A medtech PR agency helps medical-technology organizations explain their work to relevant stakeholders through communications strategy, media relations and supporting content. The buying question is whether its people and process fit your device, evidence, audience and next milestone—not simply whether it can generate publicity.
Which medtech PR agency fits your next milestone?
Start with the decision your audience must make. A clinician evaluating a technology, a procurement leader considering a supplier and a potential commercial partner will not necessarily need the same story. Your shortlist should reflect that distinction before it reflects agency size, awards or a familiar client logo.
Consider Percepture first when the brief spans PR, search visibility, owned content and commercial follow-up. Its integrated positioning is the reason for its place in this shortlist. Ask for a proposal that connects those workstreams and identifies who will implement each one.
The BCPR Group, Bellmont Partners and Escalate PR also publish relevant specialist service pages. Include them in the conversation where their stated focus matches your needs. The right medtech PR agency should be able to discuss your next milestone specifically: what changes, who cares, what supports the explanation and who acts afterward.
Compare the agencies against the same brief
Use the table as a proposal shortlist, not a performance ranking. Each medtech PR agency should answer the same questions about audience fit, scope, approval ownership and implementation. Published positioning helps identify candidates; the proposed team and working agreement determine whether the fit holds.
| Agency | Published focus | Brief to bring | Establish in the proposal |
|---|---|---|---|
| Percepture | Integrated marketing, PR, search and content | A milestone requiring coordinated media, owned-page and buyer follow-up work | Named owners, included implementation and separate visibility and commercial measures |
| The BCPR Group | MedTech PR services | A device-specific communications assignment | Relevant audience experience, evidence-review workflow and delivery team |
| Bellmont Partners | Health, medical and MedTech public relations | A health-and-medical stakeholder communications brief | Device relevance, media priorities and review responsibilities |
| Escalate PR | Medical-device and MedTech communications | A technical device narrative and media-relations assignment | Scientific translation, spokesperson access and publishing handoffs |
Give every medtech PR agency the same milestone, target audience, available evidence and internal constraints. Otherwise, an expansive proposal can look stronger than a focused one simply because the two teams priced different assignments.
Device experience versus digital-health experience
Do not use sector labels as a substitute for relevant experience. Ask candidates to explain how they would brief your intended audience, handle technical questions and work within your review process. Require examples that resemble the communication problem, not just a company operating somewhere in healthcare.
A medtech PR agency pitching a connected device should be able to separate the device explanation from software, integration and adoption questions. If your portfolio also includes pharmaceutical work, the comparison of pharmaceutical public relations firms addresses an adjacent selection decision; it should not replace device-specific evaluation.
Put the evidence boundary ahead of the launch language
Ask a medtech PR agency how it will keep the announcement, spokesperson brief, website and sales materials consistent with the source evidence. The useful answer names the documents, reviewers and approval sequence. “We understand regulated industries” is not a working process.
Use the FDA device labeling framework as a starting reference for U.S. device-labeling questions. Your regulatory and legal owners should approve the exact language for the product, intended use, jurisdiction and communication at hand. This is a communications planning guide, not product-specific regulatory advice.
Before drafting, assemble a compact evidence brief:
- Milestone: the precise event or status being announced, with its source document.
- Permitted explanation: reviewed wording for the intended use and relevant limitations.
- Supporting material: the documents available to substantiate each proposed factual statement.
- Approval owner: the person authorized to resolve questions before anything is published.
Do not let a medtech PR agency substitute “FDA approved” for the device’s actual status. Ask it to distinguish what the source says from interpretation, aspiration and promotional shorthand. Carry the same boundary into headlines, interview preparation and follow-up materials.
The MedTech Milestone-to-Trust Map
Use Percepture’s MedTech Milestone-to-Trust Map to trace a proposed story from evidence to action. This illustrative planning framework gives your medtech PR agency and internal team a shared way to identify missing decisions before outreach begins.
- Verified milestone: Define exactly what happened and identify the primary record.
- Approved evidence: Agree on the factual statements, supporting documents and limitations that can be communicated.
- Audience: Name the stakeholder and the question the announcement should help answer.
- Media and expert fit: Match the story to relevant journalists, publications and available subject-matter experts.
- Owned explanation: Publish an accessible page that explains the milestone accurately and gives interested readers a useful next step.
- Commercial follow-up: Assign incoming questions to an appropriate person and record what happens next.
Illustrative decision framework. Review the handoffs, not just the boxes. A completed release with no approved destination page is a different readiness problem from a strong page with no available spokesperson. Give each gap an owner and a resolution date.
Worked scenario: one cleared indication, one bounded story
Imagine a device manufacturer preparing an announcement about clearance for one defined indication. This is an illustrative scenario, not a client case. The marketing team has a regulatory record, reviewed intended-use wording and a spokesperson who can explain the relevant technology.
The medtech PR agency drafts a sourced announcement within that scope. The website owner prepares a matching explainer. The media lead selects audiences for whom the milestone is relevant, while the spokesperson brief distinguishes the documented development from broader product ambitions.
A proposed superiority claim has no supporting material in the brief, so it does not enter the announcement, interview notes or sales copy. If a journalist asks a question beyond the approved scope, the spokesperson routes it through the agreed review process rather than improvising.
After publication, a designated commercial owner handles appropriate inquiries. The team records which questions arise and whether the explainer answers them. That creates a concrete improvement task without turning an illustrative workflow into a promise of coverage or sales.
Separate earned media from paid placement
Require a medtech PR agency to label earned editorial, sponsored content and distribution separately. Independent editorial coverage remains the publisher’s decision. A paid format can be evaluated on its own terms, but it should not be presented as evidence that a journalist independently selected your story.
When a proposal promises a named publication, ask what is actually being sold. Is it outreach, a sponsored article, an advertising package or release distribution? Get the format, disclosure, third-party charges, reuse rights and reporting treatment in writing before comparing it with another proposal.
Your medtech PR agency should also distinguish coverage from links. A mention, a citation to a source and a clickable backlink are different deliverables or observations. The guide to earned media versus backlinks explains why the terms should not be treated interchangeably.
Judge the media plan against the sources your buyers trust, not just a list of recognizable outlets. Ask each candidate to explain the audience, proposed angle, evidence and spokesperson fit for its priority targets. A reasoned target list is more useful than a placement promise.
Meet the people who will do the work
Evaluate a medtech PR agency through its proposed delivery team, not only the people presenting the pitch. Ask who will lead the account, develop the story, contact journalists and resolve review questions. Get names, responsibilities and escalation arrangements in the proposal.
At minimum, establish these responsibilities, even when one person covers more than one role:
- Account lead: owns priorities, scope and decisions when deadlines compete.
- Media lead: owns target selection, outreach and journalist follow-up.
- Scientific or technical expert: explains the subject and checks technical meaning.
- Regulatory and legal owners: resolve the relevant claim and approval questions.
- Publishing and commercial owners: maintain the destination content and route appropriate inquiries.
Ask how those people will work together during a compressed launch. Who consolidates feedback? What happens if an expert is unavailable? Who can approve a correction? An unanswered dependency is not solved by adding another meeting to the calendar.
Before appointing a medtech PR agency, request a walkthrough of one proposed announcement using your own review constraints. Evaluate the clarity of the handoffs, the questions the team asks and whether it identifies dependencies before committing to a deadline.
Connect the public story to search and sales
A medtech PR agency brief should specify what happens after someone encounters the story. Decide whether the next useful action is reading an evidence-based explanation, asking a technical question or discussing an appropriate commercial need. Do not send every audience to the same generic page.
Where search is part of the assignment, define how digital PR services coordinate with page research, content and publishing. The medtech SEO guide addresses the search workstream; that work should have an owner rather than being assumed to happen because coverage appears.
For an AI-answer baseline, Percepture’s Prime AI Visibility provides a way to work with saved answer/source evidence and repeat comparisons. Treat a saved answer as a sample, not a universal account of what every buyer sees. Keep the question, answer and cited source distinct.
When discussing how Prime AI Visibility works, ask your medtech PR agency who will turn an observed information gap into a page action. The task might be clarifying an existing explanation or publishing a missing answer. Record the change and compare subsequent samples without promising an AI citation.
Monitoring records what appeared. Optimization changes something intended to improve the explanation or discovery path. Keep those activities separate in the scope and report; collecting another screenshot is not itself an implemented improvement.
Finally, define the commercial handoff. An inquiry is not automatically a qualified opportunity. Agree on the relevant company, role, need and next action before applying that label. The guide to selecting a medtech lead generation agency addresses that downstream brief separately.
Compare retainers by scope, ownership and exit terms
Price a medtech PR agency against a defined assignment, not an undefined promise of visibility. Compare the same launch responsibilities, ongoing activity, publishing work and review assumptions. A lower retainer with substantial excluded work is not the same purchase as a coordinated program.
Ask each proposal to separate:
- Strategy and preparation: audience research, messaging, evidence review and spokesperson preparation.
- Execution: content creation, media outreach, publishing and agreed follow-up.
- Additional costs: paid placements, distribution, travel, production or specialist support.
- Operating terms: approval turnaround, revision limits, crisis availability, ownership and termination.
For ongoing explainers and buyer education, use the guide to life science content marketing to distinguish an editorial program from a single announcement. Specify whether the retainer includes research, writing, technical review, website implementation and updates after publication.
Ask what you receive if the agreement ends: final files, approved messaging, content rights, reporting history, access handover and a record of outstanding commitments. Your medtech PR agency should explain which assets transfer and which third-party rights or subscriptions do not.
Measure outputs, audience response and commercial influence separately
Agree with your medtech PR agency on a reporting structure before work begins. Separate what the team produced from what audiences did and from later commercial activity. That makes a report useful even when a launch creates attention before a buying decision is ready.
At the output level, record completed materials, outreach and published coverage. For coverage quality, assess relevance, accuracy, message inclusion and the intended audience. Do not make a large aggregate reach figure stand in for evidence that the right stakeholders engaged.
Use PR monitoring to track appearances and emerging questions. Use PR analytics to examine the available response evidence. Keep mentions, citations, backlinks, referral visits, inquiries and opportunities in separate fields rather than combining them into one visibility score.
For commercial influence, connect available analytics and CRM records while stating the attribution limits. A medtech PR agency report should not claim that every sale following coverage was caused by PR. Review what the evidence supports, what remains a hypothesis and which action the team will take next.
MedTech PR buyer questions
When should a MedTech company start PR?
Start planning when a meaningful milestone, usable evidence and spokesperson availability can be defined. Build the review and publication schedule backward from that milestone. If the evidence is not ready, begin with buyer research, messaging and owned content rather than forcing an announcement.
Is MedTech PR the same as digital-health PR?
They overlap, but category labels are not enough. Ask for experience with your technology, stakeholder group, regulatory review and buying process. A connected-device launch and a software announcement may need different evidence, experts and media targets.
Can an agency guarantee tier-one earned coverage?
No agency controls an independent editor’s decision. Ask whether the promised placement is earned editorial, sponsored content or another paid format. Put the format, disclosure, cost and reporting treatment in the proposal.
What should a medtech PR agency proposal include?
Include the named delivery team, milestone and audience priorities, deliverables, review responsibilities, measurement definitions, fees, third-party costs, content rights, crisis arrangements and exit terms. Require the agency to distinguish what it will produce from outcomes it cannot control.
Does content marketing belong in the PR retainer?
Only when the agreement includes it. Specify who writes, reviews, publishes and updates explainers, landing pages and supporting materials. Clarify whether search research, website implementation and sales enablement are included or separately scoped.
How do you measure a medtech PR agency?
Look for relevant, accurate coverage and progress with the stakeholders you intended to reach. Report mentions, citations, referral traffic, inquiries and qualified opportunities separately. Use CRM and analytics evidence to describe commercial influence without claiming PR caused every subsequent sale.
Make the next conversation about the work
Before choosing a medtech PR agency, request a milestone, media and search-authority evaluation. Ask for the proposed story, supporting evidence, intended audience, named delivery team and commercial handoff on one page. Then compare what each candidate will actually own—not how confidently it promises exposure.
About Bob Generale
Bob Generale is President of Percepture, a global digital marketing, public relations and AI systems agency established in 2004. His work connects search strategy, digital PR, useful content and conversion planning around the questions buyers need answered. Bob’s approach starts with understanding the audience, learning how the business actually works and turning that expertise into clear explanations people can use. He advocates practical frameworks, coordinated execution and measurement that separates visibility from qualified opportunities and revenue. Prime AI Visibility is a Percepture product, reflecting his interest in making AI search insights actionable for marketing teams. For this topic, his focus is matching agency capabilities to the device milestone and stakeholder, then comparing the people and process doing the work.
